Company Description
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States.
It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system.
The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT.
It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies.
The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018.
Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
| Country | United States |
| IPO Date | May 10, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Robert J. Bitterman |
Contact Details
Address: 257 Simarano Drive Marlborough, Massachusetts United States | |
| Website | https://www.phiopharma.com |
Stock Details
| Ticker Symbol | PHIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001533040 |
| CUSIP Number | 71880W303 |
| ISIN Number | US71880W4024 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert J. Bitterman | President, Chief Executive Officer & Chairman |
| Robert M. Infarinato CPA, Esq. | Chief Financial Officer & Principal Accounting Officer |
| Caitlin Kontulis | Secretary |
| Linda M. Mahoney | Senior Vice President of Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 27, 2024 | SCHEDULE 13G | Filing |
| Dec 26, 2024 | 8-K | Current Report |
| Dec 26, 2024 | SCHEDULE 13G | Filing |
| Dec 23, 2024 | 424B5 | Filing |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 20, 2024 | 424B5 | Filing |
| Dec 19, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |